Clinical Trial Update: Safety & Efficacy of DCR-PHXC in Patients With PH1 and ESRD [Phase 2]

View source ↗

Summary

This is a Phase 2 clinical trial update describing the safety and efficacy assessment of DCR-PHXC for Primary Hyperoxaluria Type 1 in patients with End-stage re…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• End-stage Renal Disease
• Hyperoxaluria Type

Drugs mentioned

• DCR-PHXC

Snippet

Sponsor: Dicerna Pharmaceuticals, Inc., a Novo Nordisk company | Conditions: Primary Hyperoxaluria Type 1, End Stage Renal Disease | Phase 2 | Status: RECRUITING